active
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Same here guys, I get sick every time I look at REGN, over 500 bucks a share I had 10k and sold@17... thought I thought I did something????
Thanks for that info on the drugs!
Just starting my research, company certainly looks strong financially........
Balance Sheet
Total Cash (mrq) ...........:.......50.38M
Total Cash Per Share (mrq) .....2.24
Total Debt (mrq) .....................2.04M
Total Debt/Equity (mrq) .............3.90
Current Ratio (mrq) .....................8.58
Book Value Per Share (mrq) .....2.57
Low share count, NOTICE THE FLOAT
Share Statistics.........
Avg Vol (3 month) 3 75.46k
Avg Vol (10 day) 3 30.18k
Shares Outstanding 5 22.5M
Float ..................................8.41M
% Held by Insiders 1 ..........70.27%
% Held by Institutions 1 ..........14.10%
Shares Short (Mar 31, 2020) 4 51.55k
Short Ratio (Mar 31, 2020) 4 1
Short % of Float (Mar 31, 2020) 4 0.61%
Short % of Shares Outstanding (Mar 31, 2020) 4 0.23%
Shares Short (prior month Feb 28, 2020) 4 48.74k
Just starting my research here... one thing for sure, this is a Strong Company
Balance Sheet.......
Total Cash (mrq)....:..,...................,50.38M
Total Cash Per Share (mrq)...........2.24
Total Debt (mrq) .......................2.04M
Total Debt/Equity (mrq) ...............3.90
Current Ratio (mrq) ...............8.58
Book Value Per Share (mrq) .......2.57
You know, I hope you are right but unfortunately you sound a pumper/dumper that’s why I sold a few shares. This is a great Co. I invested here before the virus not because of it.
That’s GREAT to see you two guys posting over there at the beginning..... maybe one day I can get some autugraphs!
Bought more shares today@3.72!
Ready for PDUFA 5/21/2020..... LET’s GO!!!!
I think this is a GREAT LONG TERM STOCK but thought the Covin-19 was a bit much. So took a few shares and bought some AQST which has a PDUFA date coming up 5/21/2020 hopefully get a bounce and buy back more RDHL shares!
I did something I’ve never done before .......sold some RDHL @8.01 and bought more AQST@3.72
Why Nabriva Therapeutics (NBRV) Stock Might be a Great Pick
Zacks Equity Research
ZacksApril 14, 2020, 8:59 AM EDT
One stock that might be an intriguing choice for investors right now Nabriva Therapeutics plc NBRV. This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical - Biomedical and Genetics space as it currently has a Zacks Industry Rank of 20 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.
Meanwhile, Nabriva Therapeutics is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.
WOW, hadn’t noticed!!!
Have you read recent posts?
Looks like more treat left too early!
RedHill Biopharma Provides Initial Update from its Opaganib COVID-19 Compassionate Use Program in Israel
https://finance.yahoo.com/news/redhill-biopharma-provides-initial-opaganib-110010826.html
Made my watchlist... thanks again!
I like the cash strategy!
THANKS
Thanks for the tip, checking it out!
June 19, 2020 PDUFA!!!!
I really should stop also!!!!!
Same reason!
Bought more today @.52
I’m in the Red but still believe in the Co. had 10k of REGN in 1994 and sold out @$17, thought I did something but look at it now. Said to myself “If I ever find another”, methinks RDHL is it!
Doesn’t jive with your name noteteat?
I bought more today @.52, can’t seem to resist putting orders at that price!!!!!
i love this one guys keep an EYE on them!!!!
Aquestive Therapeutics' (AQST, $3.52) patented PharmFilm technology offers an effective drug delivery method that can be customized to meet the specific absorption, bioavailability and onset of action requirements. And following the company's preliminary fourth-quarter earnings release, in which it provided its first-time 2020 outlook, analysts remain with two feet on board.
Writing for RBC Capital, Randall Stanicky notes that while the guidance came in lower than he expected, he believes management is being conservative. Specifically, he points out that the company excluded contributions from Libervant, which will most likely go up for approval in late September, and said Parkinson's Disease treatment APL-130277 will only contribute a Q4 milestone payment.
Based on this development, Stanicky writes, "Our new estimates reflect these revisions though we see potential for numbers to move higher pending further visibility on Libervant launch timing and expectations."
"Overall, while our numbers have been revised modestly lower, our fundamental view of the story is unchanged; 2020 is set to be an inflection year with several updates that can drive the stock higher including anticipated approval of key value driver Libervant," continues Stanicky, who has an Outperform rating and $9 price target on AQST shares.
Stanicky's price target is the most conservative among analysts who have sounded off on this low-priced stock during the past three months. Three other Buy calls have included $10, $13 and even $36 targets, averaging out to a consensus PT of $17, or more than 380% upside over the next 52 weeks. Investors interested in learning more can see AQST analysis on TipRanks.
LOST ON THAT ONE... RMTI
ON TO AQST PDUFA DATES 5/21/2020 & 9/27/2020
Check out this potential, REMEMBER CLICK ON DRUG INFORMATION
https://www.biopharmcatalyst.com/company/AQST
LOST ON THAT ONE... RMTI
ON TO AQST PDUFA DATES 5/21/2020 & 9/27/2020
Check out this potential, REMEMBER CLICK ON DRUG INFORMATION
https://www.biopharmcatalyst.com/company/AQST
LOST ON THAT ONE... RMTI
ON TO AQST PDUFA DATES 5/21/2020 & 9/27/2020
Check out this potential, REMEMBER CLICK ON DRUG INFORMATION
https://www.biopharmcatalyst.com/company/AQST
I just checked to be one of your followers!
I hope you are right!!!
I do have hope for after many have had the weekend to meditate on it!
The PDUFA was set for Saturday 2/28/2020 and probably wasn’t thinking News would not come on Friday 2/27/2020.
Rockwell’s analyst coverage has been very favorable:
IFS SECURITIES – STRONG BUY
PIPER SANDLER – STRONG BUY
H C Wainwright – STRONG BUY
The potential for upside if the drug is approved this week could be massive.
I think you are right investor//// after the weekend maybe some will wake up!!!
OT:
The Rockwell Medical Inc. (NASDAQ:RMTI) team consists of winners from within the pharmaceutical sector, including a President and CEO who served as Corporate Officer and VP of Abbott Laboratories, leading its largest global business unit with $600 million of revenues.
Now it’s the potential for Rockwell Medical through Triferic to capture market potential in excess of $1 billion. This potential has not been ignored by the analysts currently covering and targeting Rockwell Medical Inc. (NASDAQ:RMTI).
https://microsmallcap.com/rockwell-medical-inc/RMTI-1/biotech-stock-pick/LP-G1
Rockwell’s analyst coverage has been very favorable:
IFS SECURITIES – STRONG BUY
PIPER SANDLER – STRONG BUY
H C Wainwright – STRONG BUY
The potential for upside if the drug is approved this week could be massive.\
The Rockwell Medical Inc. (NASDAQ:RMTI) team consists of winners from within the pharmaceutical sector, including a President and CEO who served as Corporate Officer and VP of Abbott Laboratories, leading its largest global business unit with $600 million of revenues.
Now it’s the potential for Rockwell Medical through Triferic to capture market potential in excess of $1 billion. This potential has not been ignored by the analysts currently covering and targeting Rockwell Medical Inc. (NASDAQ:RMTI).
Little-Known Drug Developer is on the Brink of Getting FDA Approved
The condition is… anemia.
It’s an iron deficiency disorder—often associated with diabetes mellitus or Type 2—that affects more than 2.8 million Americans1 and over 1.62 billion people worldwide5.
And with the growing prevalence of diabetes, which is projected to increase by 54% to more than 54.9 million Americans between 2015 and 2030, and increased societal costs related to the disease to increase at roughly the same rate to more than $622 billion by 20306… this new drug if approved is clearly very needed.
It’s time to take an in-depth look at a company possibly on the cusp of a major drug approval, that’s here to protect those with anemia and kidney disease.
https://microsmallcap.com/rockwell-medical-inc/RMTI-1/biotech-stock-pick/LP-G1
From the PR.......
About Triferic
Triferic is the only FDA-approved therapy in the U.S. indicated to replace iron and maintain hemoglobin in hemodialysis patients during each dialysis treatment. Triferic has a unique and differentiated mechanism of action which has the potential to benefit patients and health care economics. Triferic represents a potential innovative medical advancement in hemodialysis patient iron management– with the potential to become the future standard of care.[/The Company has two FDA-approved formulations of Triferic (1) Triferic Dialysate and (2) Triferic AVNU.
COULD YOU GIVE a or some reasons?
CONGRATS
UNBELIECABLE!!!!
I’M IN SHOCK
I guess it was a BAD DAY for GOOD NEWS.......... wow, speechless!
I’m lost!!!!